@srikosuri Agreed that next gen of drugs will succeed by not "failing completely." But the frequency of commercial success (i.e. a program that outperforms SOC), will remain low because the bar for success gets higher every year and industry is focused on "me-betters" as you say.
@vijaypande I've heard knowledgable folks say that chip evolution will make a big portion of today's capex obsolete. If you agree, does that alter your thesis?